Edarbi: a new angiotensin II antagonist

Edarbi (azilsartan medoxomil) is indicated for the treatment of essential hypertension in adults.

Edarbi: a new option for the management of hypertension
Edarbi: a new option for the management of hypertension

PHARMACOLOGY

Azilsartan medoxomil is an orally active pro-drug. It is rapidly converted to the active moiety, azilsartan, which selectively antagonises the effects of angiotensin II by blocking its binding to the AT1 receptor.1

CLINICAL STUDIES

In a 6-week randomised, double-blind, placebo-controlled trial, azilsartan medoxomil (40mg and 80mg) was compared with valsartan 320mg and olmesartan medoxomil 40mg in 1291 patients. Change from baseline in placebo-adjusted 24-hour mean systolic BP was significantly greater with azilsartan medoxomil 80mg (-14.3mmHg) than olmesartan medoxomil (-11.7mmHg; p=0.009) or valsartan (-10.0mmHg; p<0.001), and the 40mg dose of azilsartan medoxomil was non-inferior to olmesartan (difference -1.4mmHg [95% CI: -3.3 to 0.5]).2

A second 6-week study of similar design involved 1275 patients; 142 received placebo and the remainder received azilsartan medoxomil 20mg, 40mg or 80mg or olmesartan medoxomil 40mg. In this study, the reduction in 24-hour mean systolic BP was 2.1mmHg greater with azilsartan medoxomil 80mg than olmesartan medoxomil 40mg (95% CI -4.0 to -1.0; p=0.038), and azilsartan medoxomil 40mg was non-inferior to olmesartan medoxomil.3

References:

1. Edarbi Summary of Product Characteristics, December 2011.
2. White WB et al. Hypertension 2011; 57: 413-20.
3. Bakris GL et al. J Clin Hypertens 2011; 12: 81-88.

View Edarbi drug record
 
Further information: Takeda UK Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more